Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Cash & Equivalents (2016 - 2025)

Veracyte's Cash & Equivalents history spans 14 years, with the latest figure at $362.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 51.65% year-over-year to $362.6 million; the TTM value through Dec 2025 reached $362.6 million, up 51.65%, while the annual FY2025 figure was $362.6 million, 51.65% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $362.6 million at Veracyte, up from $315.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $362.6 million in Q4 2025 and bottomed at $153.4 million in Q2 2022.
  • The 5-year median for Cash & Equivalents is $205.8 million (2023), against an average of $223.0 million.
  • The largest annual shift saw Cash & Equivalents soared 122.14% in 2021 before it tumbled 53.15% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $173.2 million in 2021, then dropped by 10.94% to $154.2 million in 2022, then skyrocketed by 40.33% to $216.5 million in 2023, then increased by 10.46% to $239.1 million in 2024, then skyrocketed by 51.65% to $362.6 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Cash & Equivalents are $362.6 million (Q4 2025), $315.6 million (Q3 2025), and $219.5 million (Q2 2025).